Healthcare -
Biotechnology - NASDAQ - US
$ 6.01
1.18 %
$ 318 M
Market Cap
-3.64
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Stoke Therapeutics, Inc.
| Revenue | 36.6 M |
| Cost Of Revenue | 0 |
| Gross Profit | 36.6 M |
| Operating Expenses | 138 M |
| Operating Income | -101 M |
| Other Expenses | -12.4 M |
| Net Income | -89 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Revenue | 36.6 | 8.8 | 12.4 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||||
| Cost Of Revenue | 0 | 0 | 3.5 | 2.2 | 1.9 | 0.5 | 0.2 | 0.1 |
| Gross Profit | 36.6 | 8.8 | 8.9 | (2.2) | (1.9) | (0.5) | (0.2) | (0.1) |
| OPERATING INCOME | ||||||||
| Operating Expenses | 137.9 | 123.6 | 116.8 | 86.1 | 53.0 | 35.7 | 12.8 | 5.6 |
| Selling, General and Administrative Expenses | 48.8 | 41.3 | 38.9 | 31.9 | 20.8 | 11.9 | 4.4 | 2.0 |
| Research and Development Expenses | 89.1 | 82.2 | 77.8 | 54.2 | 32.2 | 23.8 | 8.4 | 3.6 |
| Operating Income | (101.4) | (114.8) | (104.4) | (86.1) | (53.0) | (35.7) | (12.8) | (5.6) |
| PRE-TAX INCOME | ||||||||
| Interest Income Expense | 0 | 0 | 3.1 | 0.1 | 0 | 0 | 0 | 0 |
| Total Other Income | 12.4 | 10.1 | 3.3 | 0.3 | 0.8 | 3.4 | 0.3 | 4 K |
| Pre-Tax Income | (89.0) | (104.7) | (101.1) | (85.8) | (52.2) | (32.3) | (12.5) | (5.6) |
| NET INCOME | ||||||||
| Tax Provision | 0 | 0 | (8.0) | (1.1) | (1.6) | (3.8) | 0.3 | 0 |
| Net Income | (89.0) | (104.7) | (93.1) | (84.7) | (50.6) | (28.5) | (12.5) | (5.6) |
| EPS | 1.65 | 2.38 | 2.39 | 2.31 | 1.51 | 1.59 | 0.53 | 0.43 |